Biotech Beat Nvidia in 2025. Can It Do It Again?

In this podcast, Motley Fool analysts Karl Thiel, Tom King, and Tim Beyers discuss:

The Motley Fool • Feb 11, 2026

Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist's library preparation portfolio, wi.

Business Wire • Feb 10, 2026

Twist Bioscience: Liquid Biopsy And AI Tailwinds

Twist Bioscience's stock has moved high in recent months, driven by optimism related to AI-enabled drug discovery and MRD testing. Q1 growth was modest, due in large part to an air pocket in demand caused by a large NGS customer. NGS growth is expected to rebound as the year progresses, though, supported by customers ramping up commercial testing.

Seeking Alpha • Feb 10, 2026

These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results

Twist Bioscience Corporation (NASDAQ: TWST) on Monday posted better-than-expected sales for the first quarter.

Benzinga • Feb 3, 2026

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 114,869 equity awards, consisting of 107,742 restricted stock units (“RSUs”) and up to 7,127 performance stock units (“PSUs”), will be granted to 52 recently hired individuals, in each case as an inducement material to their acceptance of employment wi.

Business Wire • Feb 3, 2026

Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript

Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript

Seeking Alpha • Feb 2, 2026

Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2026 earnings report and the investor presentation, or click https://investors.t.

Business Wire • Feb 2, 2026

Why Is Twist Bioscience Stock Soaring Monday?

Twist Bioscience Corporation (NASDAQ: TWST) on Monday posted first-quarter 2026 results of a loss of 50 cents per share, in line with the Wall Street expectations.

Benzinga • Feb 2, 2026

Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

Twist Bioscience (TWST) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.53 per share a year ago.

Zacks Investment Research • Feb 2, 2026

Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases

Twist Bioscience Corporation reported Q1 2026 revenue of $103.7M, up 17% YoY, and raised full-year guidance to $435–$440M. TWST targets adjusted EBITDA breakeven in Q4 2026, with gross margin expected above 52% for fiscal 2026. The company's DNA synthesis platform and AI-driven growth are promising, but profitability and market size remain concerns.

Seeking Alpha • Feb 2, 2026